Skip Nav Destination
Issues
1 August 2008
-
Cover Image
Cover Image
Uptake of Shiga toxin B (STxB) in primary cultures of colorectal tumors. Cells were incubated with STxB for 24 hours, fixed, and processed for immunofluorescence; STxB is shown in red and nuclear staining in blue. (A) An adenoma shows minor STxB uptake in contrast to (B) primary colorectal adenocarcinoma, (C) and liver metastasis. (D) negative control without STxB. (E) Double staining identifies the STxB-positive cells as tumor cells of epithelial origin. STxB (red) and cytokeratin-20 staining (green). (F) Note that STxB is enriched in cells at the periphery of the tumor cell islet, F-actin cytoskeleton stained in green. (G) Higher magnification shows perinuclear STxB accumulation in a tumor cell marked by cytokeratin-20 (green). (H) Fibroblasts in the primary cultures were identified by vimentin staining (green, arrowheads). The vimentin-positive cells show no uptake of STxB (red), as opposed to adjacent tumor cells (arrow). Size bars: 20 μm (A-D), 200 μm (E, F, H), 5 μm (G). For details, see Falguièes et al., in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Issue Sections
Research Articles: Therapeutics, Targets, and Development
Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1−/−/Mdr1a/1b−/− (triple-knockout) and wild-type mice
Serena Marchetti; Nienke A. de Vries; Tessa Buckle; Maria J. Bolijn; Maria A.J. van Eijndhoven; Jos H. Beijnen; Roberto Mazzanti; Olaf van Tellingen; Jan H.M. Schellens
Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology
Bernard M. Tijink; Toon Laeremans; Marianne Budde; Marijke Stigter-van Walsum; Torsten Dreier; Hans J. de Haard; C. René Leemans; Guus A.M.S. van Dongen
Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer
Tadas Vasaitis; Aashvini Belosay; Adam Schayowitz; Aakanksha Khandelwal; Pankaj Chopra; Lalji K. Gediya; Zhiyong Guo; Hong-Bin Fang; Vincent C.O. Njar; Angela M.H. Brodie
IRC-083927 is a new tubulin binder that inhibits growth of human tumor cells resistant to standard tubulin-binding agents
Anne-Marie Liberatore; Hélène Coulomb; Dominique Pons; Olivier Dutruel; Philip G. Kasprzyk; Mark Carlson; Ann Savola Nelson; Simon P. Newman; Chloe Stengel; Pierrïck Auvray; Vincent Hesry; Béatrice Foll; Nadine Narboux; Delphine Morlais; Mélissa Le Moing; Sonia Bernetiere; Raphael Dellile; Jose Camara; Eric Ferrandis; Dennis C. Bigg; Grégoire P. Prévost
Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography
L.W. Lawrence Woo; Delphine S. Fischer; Christopher M. Sharland; Melanie Trusselle; Paul A. Foster; Surinder K. Chander; Anna Di Fiore; Claudiu T. Supuran; Giuseppina De Simone; Atul Purohit; Michael J. Reed; Barry V.L. Potter
Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer
Ute Distler; Jamal Souady; Marcel Hülsewig; Irena Drmić-Hofman; Jörg Haier; Axel Denz; Robert Grützmann; Christian Pilarsky; Norbert Senninger; Klaus Dreisewerd; Stefan Berkenkamp; M. Alexander Schmidt; Jasna Peter-Katalinić; Johannes Müthing
Anti-CD30 diabody-drug conjugates with potent antitumor activity
Kristine M. Kim; Charlotte F. McDonagh; Lori Westendorf; Lindsay L. Brown; Django Sussman; Tiffany Feist; Robert Lyon; Stephen C. Alley; Nicole M. Okeley; Xinqun Zhang; Melissa C. Thompson; Ivan Stone; Hans-Peter Gerber; Paul J. Carter
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.